BTK was first identified in 1993 as a signaling molecule affected in XLA, an inherited immunodeficiency disease characterized by absence of peripheral mature B cells and serum immunoglobulins due to defect in B-cell development [16,17]. The gene discussed is BTK; the disease is Bruton-type agammaglobulinemia.